PHVS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
PHVS is not a good buy right now for an impatient investor. Despite a broadly bullish medium-term technical structure and very positive prior Phase 3 read-through reflected in higher Wall Street price targets, today’s sharp pre-market drop (-14.14% to ~23.86) breaks below key nearby support (S1 ~25.17 / pivot ~26.70) and raises near-term downside/volatility risk without any fresh news catalyst to justify stepping in immediately.
Trend/structure: Prior trend setup is bullish (SMA_5 > SMA_20 > SMA_200), suggesting the intermediate trend had been up. Momentum: MACD histogram is positive (0.159) but contracting, implying bullish momentum is fading. RSI(6) ~64.37 is neutral-to-slightly warm, not oversold (i.e., no technical ‘forced buy’). Levels: With pre-market ~23.86, price is below S1 (25.174) and even below S2 (24.233), which shifts the immediate setup bearish and suggests former supports may act as resistance on any bounce (pivot 26.698; R1 28.223). Pattern-based near-term odds: Similar-pattern projection indicates mild negative drift (-0.44% next day, -2.22% next week, -4.09% next month).
Intellectia Proprietary Trading Signals
Hedge funds/insiders: neutral (no notable recent trend).
Large pre-market drawdown (-14.14%) with no new weekly news provided to re-anchor confidence today; technically, price is breaking below key support zones, which often invites additional selling/volatility. Elevated implied volatility signals the market is pricing meaningful uncertainty. Financial profile remains loss-making with worsening YoY net loss/EPS in the latest reported quarter. No recent congress trading data to indicate influential buying support.
Latest quarter: 2025/Q3. Revenue remained at 0 (0.00% YoY). Net income fell to -37.14M (down 10.97% YoY), and EPS declined to -0.60 (down 22.08% YoY). This reflects continued pre-commercial biotech burn with losses widening year-over-year—fine for a clinical-stage story, but it does not support a ‘low-risk’ entry immediately after a sharp gap-down.
Recent analyst trend: clearly improving/bullish. On 2025-12-03, Leerink raised PT to $38 (Outperform), Morgan Stanley raised PT to $41 (Overweight), and BofA raised PT to $30 (Neutral) following positive Phase 3 RAPIDe-3 data; Morgan Stanley had also raised to $37 earlier (2025-11-13) ahead of the catalyst. Wall Street pros: differentiated rapid/durable oral on-demand profile; large/expanding HAE market; focus shifting to NDA (1H26) and prophylactic data (2H26). Wall Street cons: additional upside likely depends on prophylactic XR Phase 3 success; current price action suggests investors may be less impressed with certain endpoint magnitude details and/or are de-risking into volatility.
